Climb Bio (CLYM) Free Cash Flow (2020 - 2026)

Climb Bio (CLYM) has 7 years of Free Cash Flow data on file, last reported at -$14.4 million in Q1 2026.

• Quarterly Free Cash Flow rose 6.9% year-over-year to -$14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.8 million (down 86.49% YoY) and the FY2025 annual result came in at -$55.9 million, down 254.46% from the prior year.
• Free Cash Flow climbed to -$14.4 million in Q1 2026, from -$15.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $3.5 million in Q3 2023 to a low of -$15.6 million in Q4 2025.
• A 5-year average of -$8.5 million and a median of -$8.4 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 183.59% — and 2025, when it sank 1581.26%.
• Tracing CLYM's Free Cash Flow over 5 years: stood at -$8.4 million in 2022, then jumped by 88.79% to -$947000.0 in 2023, then slumped by 505.7% to -$5.7 million in 2024, then sank by 172.58% to -$15.6 million in 2025, then increased by 8.03% to -$14.4 million in 2026.
• The last three Free Cash Flow figures came in at -$14.4 million (Q1 2026), -$15.6 million (Q4 2025), and -$13.6 million (Q3 2025), per Business Quant data.